ATE370232T1 - Anti-apo-2 antikörper - Google Patents

Anti-apo-2 antikörper

Info

Publication number
ATE370232T1
ATE370232T1 AT98926036T AT98926036T ATE370232T1 AT E370232 T1 ATE370232 T1 AT E370232T1 AT 98926036 T AT98926036 T AT 98926036T AT 98926036 T AT98926036 T AT 98926036T AT E370232 T1 ATE370232 T1 AT E370232T1
Authority
AT
Austria
Prior art keywords
apo
antibodies
chimeras
nucleic acid
acid encoding
Prior art date
Application number
AT98926036T
Other languages
English (en)
Inventor
Avi Ashkenazi
Camellia Adams
Anan Chuntharapai
Kyung Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26693808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE370232(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE370232T1 publication Critical patent/ATE370232T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98926036T 1997-05-15 1998-05-14 Anti-apo-2 antikörper ATE370232T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85721697A 1997-05-15 1997-05-15
US2074698A 1998-02-09 1998-02-09

Publications (1)

Publication Number Publication Date
ATE370232T1 true ATE370232T1 (de) 2007-09-15

Family

ID=26693808

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07002962T ATE516354T1 (de) 1997-05-15 1998-05-14 Apo-2-rezeptor
AT98926036T ATE370232T1 (de) 1997-05-15 1998-05-14 Anti-apo-2 antikörper

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07002962T ATE516354T1 (de) 1997-05-15 1998-05-14 Apo-2-rezeptor

Country Status (12)

Country Link
US (1) US20030017161A1 (de)
EP (2) EP1860187B1 (de)
JP (3) JP2001511653A (de)
AT (2) ATE516354T1 (de)
CA (1) CA2287911C (de)
CY (1) CY1106966T1 (de)
DE (1) DE69838249T3 (de)
DK (2) DK1860187T3 (de)
ES (1) ES2293682T5 (de)
IL (1) IL132067A0 (de)
PT (2) PT981618E (de)
WO (1) WO1998051793A1 (de)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US7803615B1 (en) * 1997-03-17 2010-09-28 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
EP1788086A1 (de) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Rezeptor 5, der eine für den Zelltod verantwortliche Domäne enthält
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
AU9376498A (en) * 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
DE69941453D1 (de) * 1998-06-12 2009-11-05 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
DE60042066D1 (de) * 1999-05-28 2009-06-04 Genentech Inc Chimärische dr4 antikörper und ihre verwendung
CA2375149A1 (en) * 1999-06-09 2000-12-14 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
JP5118796B2 (ja) 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
JP2003510253A (ja) * 1999-09-15 2003-03-18 ジェネンテック・インコーポレーテッド Ａｐｏ−２レセプター抗体
ATE383374T1 (de) * 2000-02-11 2008-01-15 Genetics Inst Llc Verwendung der extrazellulären domäne von trade molekülen in medikamenten zur behandlung von neoplasie
ATE511857T1 (de) 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
EP1303293B1 (de) 2000-07-27 2008-12-03 Genentech, Inc. Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
AU2002256895B2 (en) 2001-05-18 2008-09-18 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
ES2437992T3 (es) * 2001-05-25 2014-01-15 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
PT1409544E (pt) 2001-07-03 2009-09-16 Genentech Inc Anticorpos de dr4 humanos e suas utilizações
JP2005508162A (ja) 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
DK1450847T3 (da) 2001-11-13 2010-12-13 Genentech Inc Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
CA2471140A1 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6870034B2 (en) 2002-02-05 2005-03-22 Genentech, Inc. Protein purification
US20060234226A1 (en) 2002-04-26 2006-10-19 Fahner Robert L Non-affinity purification of proteins
JP4574350B2 (ja) 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
DK1648940T3 (en) 2003-07-28 2016-08-15 Genentech Inc Reduction of leaching of protein A during protein A affinity chromatography
EP1531162A1 (de) * 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
NZ551428A (en) * 2004-06-18 2010-03-26 Genentech Inc Use of apo2L receptor agonists and NK cells or NK cell activators
CA2575152A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Method for predicting sensitivity of mammalian cells to apo2l/trail comprising deletion of biomarker expression
EP2292794A3 (de) 2004-08-06 2011-07-06 Genentech, Inc. DR Antikörper zur pharmazeutischen Verwendung und Verfahren zur Vorhersage der Sensitivität von Zellen gegenüber solchen Antikörpern mittels Biomarkern
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8129124B2 (en) 2005-02-02 2012-03-06 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
ZA200706246B (en) * 2005-02-02 2008-11-26 Genentech Inc DR5 antibodies and uses thereof
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
AU2006279578A1 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensivity to Apo2L/TRAIL by testing for GalNac-T14 expression in cells/tissues
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
EP2289909B1 (de) 2005-11-30 2014-10-29 AbbVie Inc. Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2470941C2 (ru) 2005-12-02 2012-12-27 Дженентек, Инк. Связывающие полипептиды и их применения
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
KR101431856B1 (ko) 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
HUE061746T2 (hu) 2007-07-09 2023-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
EP3441402A1 (de) 2007-10-30 2019-02-13 Genentech, Inc. Antikörperreinigung durch kationenaustauschchromatographie
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
DK3604324T3 (da) 2008-08-14 2024-04-08 Genentech Inc Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
CN102209554A (zh) 2008-09-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
US20100105620A1 (en) 2008-10-10 2010-04-29 Anaphore, Inc. Polypeptides that bind Trail-R1 and Trail-R2
WO2010074953A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Stirred tank reactor and method
JP2012512244A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
EP3263583A1 (de) 2010-02-12 2018-01-03 Pharmascience Inc. Iap-bir-domänen bindende verbindungen
CA2791652C (en) 2010-03-02 2018-06-12 Kyowa Kirin Co., Ltd. Modified antibody composition
EP2550018B1 (de) 2010-03-22 2019-02-27 F.Hoffmann-La Roche Ag Zusammensetzungen und verfahren zur stabilizierung von proteinen enthaltenden formulierungen
WO2011118739A1 (ja) 2010-03-26 2011-09-29 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
BR112012030197A2 (pt) 2010-05-28 2015-09-29 Genentech Inc diminuição do nível de lactato e aumento da produção de poliptídeo por subregulação da expressão de lactato desidrogenase e piruvato desidrogenase cinase.
SI2585045T1 (sl) 2010-06-24 2019-11-29 Hoffmann La Roche Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
WO2012017925A1 (ja) 2010-08-02 2012-02-09 協和発酵キリン株式会社 物質の製造方法
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
SG189456A1 (en) 2010-10-29 2013-05-31 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
KR102058658B1 (ko) 2010-12-15 2019-12-24 다이가쿠쿄도리요우키칸호우진 죠우호우시스테무 겡큐키코우 단백질의 생산 방법
JP5882913B2 (ja) 2010-12-27 2016-03-09 協和発酵キリン株式会社 培地およびキレート剤を含む水溶液の調製方法
EP2681238A2 (de) 2011-02-28 2014-01-08 Istituto di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo- Ospedale di Alta Specializzazione E di Rilievo Apoptoseinduzierende moleküle und verwendungen davon
MX2013012716A (es) 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
US20130012689A1 (en) 2011-07-08 2013-01-10 Emd Millipore Corporation Depth Filters For Disposable Biotechnological Processes
ES2697676T3 (es) 2011-12-22 2019-01-25 Hoffmann La Roche Cromatografía de membrana de intercambio iónico
US20140080180A1 (en) 2012-03-27 2014-03-20 Genentech, Inc. Harvest operations for recombinant proteins
JP6254581B2 (ja) 2012-05-18 2017-12-27 ジェネンテック， インコーポレイテッド 高濃度モノクローナル抗体製剤
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
ES2812208T3 (es) 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
SG11201700097WA (en) 2014-07-09 2017-02-27 Genentech Inc Ph adjustment to improve thaw recovery of cell banks
US10849912B2 (en) 2016-02-09 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
WO2017172994A1 (en) 2016-03-29 2017-10-05 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
EP3323428A1 (de) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selektive c-flip-hemmer als antikrebsmittel
JP7553241B2 (ja) 2016-12-22 2024-09-18 ジェネンテック， インコーポレイテッド 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US12018045B2 (en) 2018-03-06 2024-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
KR102870511B1 (ko) 2018-07-03 2025-10-15 브리스톨-마이어스 스큅 컴퍼니 재조합 단백질 생산 방법
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
WO2020091041A1 (ja) 2018-11-02 2020-05-07 協和キリン株式会社 液体培地の調製方法
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN113993885B (zh) 2019-04-12 2025-04-25 格尔托公司 重组弹性蛋白及其生产
WO2021021973A1 (en) 2019-08-01 2021-02-04 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
CA3160574A1 (en) 2019-12-03 2021-06-10 Fubin LI Antibody fc region having enhanced binding affinty to fcyriib
EP3910331A1 (de) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intrazelluläre kinase in verbindung mit resistenz gegen t-zell-vermittelte zytotoxizität und verwendungen davon
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
WO2022154664A1 (en) 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5153118A (en) * 1985-12-17 1992-10-06 Eastern Virginia Medical Authority Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
CA1306430C (en) * 1987-10-16 1992-08-18 Kenneth Francis Bradstock Monoclonal antibody
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0510691B1 (de) * 1991-04-26 2004-11-03 Osaka Bioscience Institute Für ein menschliches Zelloberflächen-Antigen kodierende DNS
US5216126A (en) * 1991-06-19 1993-06-01 Genentech, Inc. Receptor polypeptides and their production and uses
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) * 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US7803615B1 (en) * 1997-03-17 2010-09-28 Human Genome Sciences, Inc. Death domain containing receptor 5
CA2287085A1 (en) * 1997-04-16 1998-10-22 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
CA2301202A1 (en) * 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20020048566A1 (en) * 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
CA2471140A1 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
EP1860187A1 (de) 2007-11-28
ATE516354T1 (de) 2011-07-15
JP2008148695A (ja) 2008-07-03
ES2293682T3 (es) 2008-03-16
CA2287911C (en) 2014-05-06
EP0981618B2 (de) 2011-08-24
DK1860187T3 (da) 2011-10-31
CY1106966T1 (el) 2012-09-26
EP1860187B1 (de) 2011-07-13
DE69838249T3 (de) 2012-01-19
DK0981618T3 (da) 2007-11-26
EP0981618A1 (de) 2000-03-01
PT1860187E (pt) 2011-10-04
DE69838249T2 (de) 2008-05-15
US20030017161A1 (en) 2003-01-23
AU740858B2 (en) 2001-11-15
JP2001511653A (ja) 2001-08-14
HK1109423A1 (en) 2008-06-06
DK0981618T4 (da) 2011-11-21
EP0981618B1 (de) 2007-08-15
IL132067A0 (en) 2001-03-19
CA2287911A1 (en) 1998-11-19
JP2010075184A (ja) 2010-04-08
WO1998051793A1 (en) 1998-11-19
AU7796398A (en) 1998-12-08
ES2293682T5 (es) 2011-11-17
PT981618E (pt) 2007-11-23
DE69838249D1 (de) 2007-09-27

Similar Documents

Publication Publication Date Title
ATE370232T1 (de) Anti-apo-2 antikörper
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
DE69528061D1 (de) Gereinigte polyporus laccasen und dafür kodierende nukleinsäuren
DE60144145D1 (de) Subtilisin-variante
BR0012759A (pt) Neurotoxinas recombinantes ativáveis
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
DE69836088D1 (de) Als lerk6 bezeichnetes cytokin
ATE291897T1 (de) Verwendung von zusammensetzungen mit stabilisierten enzymen
ATE362985T1 (de) Apo-2 ligand
ATE196164T1 (de) Gereinigte scytalidium lacassen und nukleinsäuren dafür kodierend
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
TR199900903T2 (xx) Bir t�m�r nekroz fakt�r� ailesine ili�kin protein
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
WO2001019861A3 (en) Apo-2 receptor antibodies
ATE443761T1 (de) Rtd receptor
ATE315092T1 (de) Acetylhydrolase des plättchen aktivierenden faktors, und entsprechendes gen
DE69737476D1 (de) Neuer galaninrezeptor
ATE236983T1 (de) Durch zelldichte stimulierte protein-tyrosin- phosphatasen
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
SE9604439D0 (sv) New receptor
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0981618

Country of ref document: EP